Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. Co. delivers its approved medicines, AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), to patients in the U.S. and Europe, and it is globally developing multiple programs for systemic mastocytosis lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Co. is developing a portfolio of investigational EGFR inhibitors such as BLU-945, BLU-701, BLU-525 and BLU-451, to address a range of common and uncommon epidermal growth factor receptor activating mutations, including exon 19 deletions, the L858R mutation and exon 20 insertions. The BPMC average annual return since 2015 is shown above.
The Average Annual Return on the BPMC average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BPMC average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BPMC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|